PET/CT following intensity-modulated radiation therapy for primary lung tumor in a dog

Veterinary Radiology and Ultrasound

Volumn 47, Issue 2, 2006, Pages 228-233

  Ballegeer, Elizabeth A ^a   Forrest, Lisa J ^a   Jeraj, Robert ^b   Mackie, T Rockwell ^b   Nickles, R Jerome ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

18F fluorodeoxyglucose; 18F fluorothymidine; Intensity modulated radiation therapy; Positron emission tomography; Primary lung tumor

Indexed keywords

CANIS FAMILIARIS;

DIAGNOSTIC AGENT; FLUORINE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DOG; DOG DISEASE; FEMALE; LUNG TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645736279     PISSN: 10588183     EISSN: 17408261     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2006.00132.x     Document Type: Article

References (52)

1. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175: 356-373.
2. Coleman RE. Single photon emission computed tomography and positron emission tomography in cancer imaging. Cancer 1991;67(Suppl 4):1261-1270.
3. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003;55:5-15.
4. Mankoff DA, Dehdashti F, Shield AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptor. Neoplasia 2000;2:71-88.
5. Leskinen-Kallio S. Positron emission tomography in oncology. Clin Physiol 1994;14:329-335.
6. Ito K, Kato T, Ohta T, et al. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996;23:1372-1377.
7. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002;53:89-112.
8. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-75.
9. Kostakoglu L, Agress H Jr., Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-340.
10. Rege SD, Chaiken L, Hoh CK, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993;189:807-812.
11. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-708.
12. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757-1762.
13. Chaiken L, Rege S, Hoh C. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455-464.
14. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-17.
15. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988;29:1521-1525.
16. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-4208.
17. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
18. Kubota R, Yamada S, Kubota K, Ishiwata K, Yamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
19. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38:280-287.
20. Haberkorn U, Bellemann ME, Brix G, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 2001;28:418-425.
21. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648. discussion 649-650.
22. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116.
23. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001(Suppl): 96S-103S.
24. Munch-Petersen B, Cloos L, Jensen HK, et al. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
25. Cleaver JE. Thymidine metabolism and cell kinetics. Front Biol 1967;6:43-100.
26. Shields AF, Coonrod DV, Quackenbush RC, Crowley JJ. Cellular sources of thymidine nucleotides: studies for PET. J Nucl Med 1987;28:1435-1440.
27. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994;30:391-398.
28. Vander Borght T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994;35:974-982.
29. 11C-thymidine activity in human head and neck tumors using positron emission tomography (PET). Acta Oncol 1992;31:539-543.
30. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988;29:1633-1637.
31. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990;31:337-342.
32. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336.
33. Francis DL, Loizidou M, Visvikis D, et al. Monitoring 5-fluorouracil chemotherapy response in colorectal cancer using positron emission tomography. Eur J Surg Oncol 2003;29:789.
34. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31:720-724.
35. 18F]FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 2003;30:1407-1412.
36. 18F]-FDG. J Nucl Med 2003;44:1426-1431.
37. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine. Clin Cancer Res 2004;10:1685-1690.
38. 18F]-FDG PET. J Nucl Med 2004;45:226-231.
39. 18F-fluoro-3′-deoxy-L-thimidine: a new tracer for staging metastatic melanoma? J Nucl Med 2003;44:1927-1932.
40. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-1469.
41. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-3798.
42. Krohn KA. Evaluation of alternative approaches for imaging cellular growth. Q J Nucl Med 2001;45:174-178.
43. Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995105:135-139.
44. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-1359.
45. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
46. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(Suppl 5):1S-93S.
47. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260.
48. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro- D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135-141.
49. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-620.
50. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-522.
51. Koss LG, Woyke S, Olszewski W. Aspiration biopsy: Cytologic interpretation and histologic bases. Tokyo: Igaku-Shoin Medical Publishers, 1984.
52. Rubin P, Constine LS, Williams JP. Late effects of cancer treatment: radiation and drug toxicity. In: Principles and practice of radiation oncology Perez CA, Brady LW (eds). Philadelphia: Lippincott-Raven, 1998;196.